Risk Stratification in Vascular Disease Patients
In this seriesClinical Pearl4
Why Was This Research Needed?
How can clinicians accurately identify the highest risk vascular patients for adverse cardiovascular and limb events?
Bottom Line
Polyvascular disease significantly raises the risk of major adverse cardiovascular and limb events among patients; clinicians should prioritize these patients for enhanced therapeutic strategies. Identifying patients above the age of 75, with diabetes, heart failure, or chronic renal insufficiency should also inform treatment plans.
Study at a Glance
- Study Design
- Registry study
- Population
- 5,532 patients with CAD and/or PAD
- Intervention
- Low dose rivaroxaban (2.5 mg BID) plus aspirin
- Primary Outcome
- Major adverse cardiovascular events (MACE) and major adverse limb events (MALE) incidence rates
Key Findings
- Patients with polyvascular disease had an incidence risk of MACE or MALE of 9.16 per 100 patient-years compared to 2.48 for nonpolyvascular patients.
- Participants aged 75 or older exhibited elevated risks, reinforcing the necessity for intensified monitoring and treatment.
- Diabetes, heart failure, and chronic renal insufficiency further stratified risk, necessitating a careful approach to management.
Implications for Practice
Incorporating risk factors like polyvascular disease, age, and comorbidities into routine assessments will aid in identifying patients needing maximized antithrombotic therapy. This stratification should guide clinicians in prioritizing resources and therapeutic interventions more effectively.
Caveats & Limitations
Findings are drawn from a single-arm registry and may require validation in larger, heterogeneous populations.